What is IGC Pharma, Inc.?
, a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. The company is listed on the AMEX in USA, operating in the Healthcare sector, with a market capitalisation of 19.60M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.